Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the second quarter 2025, in conjunction with their partner Biogen's ...

Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S.

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...